Click here to download a PDF version of our Scope Newsletter
Scope 40
Click here for a downloadable pdf of Scope 40.
Alternatively, in this edition of Scope, published in October 2009:
From theory to therapy
For the past decade the Malaghan Institute has been focussed on translating our basic biomedical research into real results for patients. Turning a novel theory into a therapy that is practiced in the clinic however, is not a trivial process. Read More
Cancer treatment options: surgery, drugs, radiation... the immune system
An area of rapid growth at the Malaghan Institute is our cancer vaccine immunotherapy programme. Read More
Breaking news - Malaghan Institute joins effort to cure breast cancer
In the first of its kind for the Malaghan Institute, our considerable knowledge and clinical expertise in dendritic cell-based cancer immunotherapy will now also be applied to breast cancer. Read More
Protecting our children from Rotavirus
Complementing the Institute's cancer vaccine programme is the research of the Infectious Diseases group, whose ultimate goal is to use vaccination to reduce the incidence of infectious disease in New Zealand. Read More
Why are some people more prone to gout?
The goal of our cancer immunotherapy programme and infectious diseases research is to turn on the immune system. To treat gout however, we need to turn it off. Read More
Latest News
Minister of Health visits Institute, Send us your email address, Exciting new Auckland fundraising initiative. Read More
Malaghan Institute Open Day
To celebrate its 30 year history of pioneering research into the immune system and how it can be harnessed for the treatment of diseases such as cancer, asthma, arthritis, multiple sclerosis and infectious disease, the Malaghan Institute of Medical Research opened its doors to the general public of Wellington on Sunday, 9 August 2009. Read More
Whats been happening...
Just Paterson, Annual Report note, Golf Tournaments, Lollipop Appeal call for volunteers, Spot prize winners, Buzz Channel surveys. Read More
